Exact Sciences stock plunged more than 20% late Thursday morning based on what was ostensibly positive early news about a massive pivotal study for the company's colorectal cancer molecular diagnostic test. While the data met all endpoints, investors clearly wanted better and they punished the company as a result.
Cancer diagnostics startup CvergenX will work jointly with the National Cancer Institute to develop a new diagnostic that would predict the likely success of radiation therapy. The goal is to bring the test to market within three years.
U.K. scientists came up with a way to more efficiently detect a crucial colorectal cancer biomarker. They've even created a new word to describe the diagnostic process: "spinostics."
Researchers at MIT have found a nanoparticle solution that can ramp up biomarker production and make cancer diagnostics a little easier
Fresh off some promising data for its stool-based cancer diagnostic, Exact Sciences is knocking on the FDA's door for full approval, filing part one of a three-step PMA for the assay.
A treatment as cheap and simple as aspirin can make some patients with colorectal cancer live longer, but it doesn't work for everyone. Researchers from the U.S. and Japan have pinpointed a mutation in a single gene that could find the patients that this could help.
Data on Exact Sciences' colorectal cancer screening test suggest that the assay could pick up the DNA changes and traces of blood that signal precancers and the very earliest stages of cancer, when treatment is at its most effective.
Three months after landing FDA fast-track review status for regorafenib , Bayer 's top cancer prospect, today the agency delivered an approval as a treatment for colorectal cancer . The approval comes after a tumultuous lawsuit filed in 2009 by Onyx Pharmaceuticals ( $ONXX ), claiming the compound can be distinguished from Nexavar by only a single atom. Here's a look back at regorafenib's history.
Only three months after nabbing FDA fast-track review status for regorafenib, Bayer's top cancer prospect, the agency handed out a speedy approval this afternoon as a new treatment for metastatic colorectal cancer. The double-quick regulatory OK completes Bayer's quick sprint through the late-stage development process, paving the way to commercialization work expected to generate peak sales of $1.25 billion a year or more.
A group of Spanish institutions are collaborating to develop an early test for colorectal cancer, the second-highest cause of cancer death in the Western world, killing 50,000 people every year.